Related Experiment Videos

Pediatric granulomatous arthritis: an international registry

Carlos D Rosé1, Carine H Wouters, Silvia Meiorin

  • 1duPont Children's Hospital, Wilmington, Delaware 19899, USA. crose@nemours.org

Arthritis and Rheumatism
|September 30, 2006
PubMed

Insights

Pediatric granulomatous arthritis, including Blau syndrome and early-onset sarcoidosis, is linked to CARD15 mutations. Mutation analysis may be more efficient than skin biopsy for diagnosis.

Area of Science:

  • Genetics
  • Rheumatology
  • Ophthalmology

Background:

  • Blau syndrome and early-onset sarcoidosis share a phenotype of arthritis, dermatitis, and uveitis.
  • CARD15 mutations are found in 50-90% of these cases.
  • An international registry was created to study pediatric granulomatous arthritis.

Purpose of the Study:

  • To define the phenotype spectrum of pediatric granulomatous arthritis.
  • To establish CARD15 mutation frequency and variants.
  • To compare diagnostic approaches.

Main Methods:

  • Established an international registry for pediatric granulomatous arthritis.
  • Required histological confirmation of granuloma and arthritis for inclusion.
  • Genotyped probands and relatives for CARD15 mutations.

Main Results:

  • 61 individuals from 22 pedigrees were entered within one year.
  • Classic pediatric granulomatous arthritis pedigrees carried CARD15 mutations; atypical cases did not.
  • Cutaneous presentation was most common; 41% experienced severe visual impairment, often bilateral, with glaucoma and cataracts.

Conclusions:

  • All affected classic pediatric granulomatous arthritis pedigrees carry CARD15 mutations, with no asymptomatic carriage.
  • Mutation analysis may be more efficient than tissue sampling for diagnosis.
  • Further defined the phenotype of pediatric granulomatous arthritis.
Abstract

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...